Trial Profile
Prediction of the effectiveness and safety of nivolumab for non-small cell lung cancer patients: a retropective cohort study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
- 13 May 2016 New trial record